“Durability of Response in Patients With Chronic Plaque Psoriasis Treated With Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S87. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/484.